{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T04:40:51Z","timestamp":1765082451961,"version":"3.46.0"},"reference-count":42,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,10,16]]},"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Smoking is a major avoidable cause of ill-health and premature death. Treatments that help patients successfully quit smoking have an important effect on health and life expectancy. Varenicline is a medication that can help smokers successfully quit smoking. However, there are concerns that it may cause adverse effects, such as increase in the occurrence of depression, self-harm and suicide and cardiovascular disease. In this study we aim to examine the effects of varenicline versus other smoking cessation pharmacotherapies on smoking cessation, health service use, all-cause and cause-specific mortality and physical and mental health conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this project we will investigate the effects of varenicline compared to nicotine replacement therapies on: (1) long-term smoking cessation and whether these effects differ by area level deprivation; and (2) the following clinically-important outcomes: rate of general practice and hospital attendance; all-cause mortality and death due to diseases of the respiratory system and cardiovascular disease; and a primary care diagnosis of respiratory illness, myocardial infarction or depression and anxiety. The study is based on a cohort of patients prescribed these smoking cessation medications from the Clinical Practice Research Datalink (CPRD). We will use three methods to overcome confounding: multivariable adjusted Cox regression, propensity score matched Cox regression, and instrumental variable regression. The total expected sample size for analysis will be at least 180\u2005000. Follow-up will end with the earliest of either an \u2018event\u2019 or censoring due to the end of registration or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was not required for this study. This project has been approved by the CPRD's Independent Scientific Advisory Committee (ISAC). We will disseminate our findings via publications in international peer-reviewed journals and presentations at international conferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009665","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T21:04:18Z","timestamp":1446843858000},"page":"e009665","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study"],"prefix":"10.1136","volume":"5","author":[{"given":"Neil M","family":"Davies","sequence":"first","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Taylor","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy E","family":"Taylor","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK"},{"name":"School of Experimental Psychology, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyla H","family":"Thomas","sequence":"additional","affiliation":[{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Windmeijer","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK"},{"name":"Department of Economics, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M","family":"Martin","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus R","family":"Munaf\u00f2","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK"},{"name":"School of Experimental Psychology, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.1","DOI":"10.1136\/bmj.321.7257.323"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.2","DOI":"10.1056\/NEJMra1308383"},{"unstructured":"Health D of. Smoking kills: a White Paper on tobacco. 1998 (cited 2014 Jun 20). http:\/\/webarchive.nationalarchives.gov.uk\/+\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_4006684","key":"2025120619061713000_5.11.e009665.3"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.4","DOI":"10.1192\/bjp.bp.110.081372"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.5","DOI":"10.1371\/journal.pone.0019590"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.6","DOI":"10.1136\/tc.2008.026294"},{"key":"2025120619061713000_5.11.e009665.7","first-page":"CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"5","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120619061713000_5.11.e009665.8","first-page":"2","article-title":"Varenicline: adverse psychiatric reactions, including depression","volume":"2","author":"Medicines and Healthcare Products Regulatory Agency","year":"2008","journal-title":"Drug Saf Update"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.9","DOI":"10.1136\/bmj.e2856"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.10","DOI":"10.1503\/cmaj.110218"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.11","DOI":"10.1136\/bmj.h1109"},{"unstructured":"Drug Safety and Availability > FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events (cited 23 September 2014). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm276737.htm","key":"2025120619061713000_5.11.e009665.12"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.13","DOI":"10.1136\/bmj.f5704"},{"unstructured":"Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders\u2014Full Text View\u2014ClinicalTrials.gov (cited 20 June 2015). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01456936","key":"2025120619061713000_5.11.e009665.14"},{"unstructured":"FDA. FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking (cited 20 June 2015). http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM436960.pdf","key":"2025120619061713000_5.11.e009665.15"},{"key":"2025120619061713000_5.11.e009665.16","first-page":"1226","article-title":"Smoking-attributable mortality, years of potential life lost, and productivity losses\u2013United States, 2000\u20132004","volume":"57","author":"Control C for D, (CDC P, others","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.17","DOI":"10.1016\/j.drugalcdep.2014.03.001"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.18","DOI":"10.1111\/bcp.12059"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.19","DOI":"10.1002\/pds.1960"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.20","DOI":"10.1097\/EDE.0b013e3181875e61"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.21","DOI":"10.1136\/bmjopen-2014-004958"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.22","DOI":"10.1002\/pds.3537"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.23","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.24","DOI":"10.1136\/bmjopen-2014-005540"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.25","DOI":"10.1136\/bmj.330.7488.389"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.26","DOI":"10.1016\/0021-9681(87)90171-8"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.27","DOI":"10.1186\/1471-2296-11-1"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.28","DOI":"10.1093\/ije\/dyp334"},{"unstructured":"Kirkwood BR . Essential medical statistics. 2nd edn. Malden, MA: Blackwell Science; 2003:501 p.","key":"2025120619061713000_5.11.e009665.29"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.30","DOI":"10.1111\/j.1742-7843.2006.pto_293.x"},{"unstructured":"Leuven E , Sianesi B . PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Stat Softw Compon 2012 (cited 13 May 2013). http:\/\/ideas.repec.org\/c\/boc\/bocode\/s432001.html","key":"2025120619061713000_5.11.e009665.31"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.32","DOI":"10.2307\/2683903"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.33","DOI":"10.1093\/biomet\/70.1.41"},{"key":"2025120619061713000_5.11.e009665.34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/EDE.0b013e318289e024","article-title":"COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis","volume":"24","author":"Davies","year":"2013","journal-title":"Epidemiology"},{"key":"2025120619061713000_5.11.e009665.35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jclinepi.2013.06.008","article-title":"Physicians\u2019 prescribing preferences were a potential instrument for patients\u2019 actual prescriptions of antidepressants","volume":"66","author":"Davies","year":"2013","journal-title":"J Clin Epidemiol"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.36","DOI":"10.1080\/01621459.2012.734171"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.37","DOI":"10.2307\/1911873"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.38","DOI":"10.1093\/biostatistics\/kxq024"},{"unstructured":"Stata Statistical Software: Release 13. College Station, TX: StataCorp LP, 2013.","key":"2025120619061713000_5.11.e009665.39"},{"unstructured":"Baum CF , Schaffer ME , Stillman S . ivreg2: Stata module for extended instrumental variables\/2SLS, GMM and AC\/HAC, LIML and k-class regression. 2010. http:\/\/ideas.repec.org\/c\/boc\/bocode\/s425401.html (accessed 6 Aug 2015).","key":"2025120619061713000_5.11.e009665.40"},{"unstructured":"Office of National Statistics. Do smoking rates vary between more and less advantaged areas?. 2014 (cited 8 October 2014). http:\/\/www.ons.gov.uk\/ons\/rel\/disability-and-health-measurement\/do-smoking-rates-vary-between-more-and-less-advantaged-areas-\/2012\/sty-smoking-rates.html","key":"2025120619061713000_5.11.e009665.41"},{"doi-asserted-by":"publisher","key":"2025120619061713000_5.11.e009665.42","DOI":"10.2307\/2291629"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:06:24Z","timestamp":1765076784000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,5]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/bmjopen-2015-009665"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009665","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}